Claims
- 1. A humanized immunoglobulin, which is a humanized version of the mouse AF2 immunoglobulin having a light chain variable region designated SEQ ID No:2 and a heavy chain variable region designated SEQ ID No:4, the humanized immunoglobulin comprising humanized heavy and light chains, provided that position 11 of the humanized heavy chain variable region framework is occupied by the amino acid present in the equivalent position of the mouse AF2 heavy chain variable region framework.
- 2. The humanized immunoglobulin of claim 1, comprising CDRs from the mouse AF2 immunoglobulin and heavy and light chain variable region frameworks from the human EU immunoglobulin.
- 3. The humanized immunoglobulin of claim 2, further provided that position H38 is occupied by the amino acid present in the equivalent position of the mouse AF2 heavy chain variable region framework.
- 4. The humanized immunoglobulin of claim 2, further provided that positions H11, H27, H28, H30, H38, H48, H67, H68, H70, H72, H74, H93, H95, H98, H107, H108, H109, H111 are occupied by the amino acid present in the equivalent position of the mouse AF2 heavy chain, positions L48, and L70 are occupied by the amino acid present in the equivalent position of the mouse AF2 light chain, and position L63 is occupied by the amino acid present in the equivalent position of a consensus sequence of light chains of human immunoglobulins.
- 5. The humanized immunoglobulin of claim 1 that specifically binds to human γ-IFN with an affinity constant within four-fold of the affinity of the mouse AF2 antibody.
- 6. The humanized immunoglobulin of claim 1 that specifically binds to γ-IFN comprising a humanized mature light chain having at least 90% sequence identity to the mature light chain of SEQ ID No:6, and a humanized mature heavy chain having at least 90% sequence identity to the mature heavy chain of SEQ ID No:8.
- 7. The humanized immunoglobulin according to claim 1 that comprises two light chain/heavy chain dimers.
- 8. The humanized immunoglobulin of claim 1 that is of IgGl isotype.
- 9. The humanized immunoglobulin according to claim 1, which is purified to at least 95% homogeneity.
- 10. A humanized immunoglobulin comprising a mature heavy chain variable region designated SEQ ID No:6 and a mature light chain variable region designated SEQ ID No:8.
- 11. A pharmaceutical composition comprising a humanized immunoglobulin of claim 1 or 10 and a pharmaceutically acceptable carrier.
- 12. A method of treating a patient suffering from a harmful immune response, comprising administering a therapeutically effective dosage of the pharmaceutical composition of claim 1 or 10.
- 13. The method of claim 12, wherein the patient is suffering from an autoimmune disease.
CROSS-REFERENCE TO RELATED APPLICATIONS
[0001] This application claims priority from provisional patent application U.S. Ser. No. 60/110,523, filed Dec. 1, 1998, the disclosure of which is incorporated herein by reference.
Provisional Applications (1)
|
Number |
Date |
Country |
|
60110523 |
Dec 1998 |
US |
Continuations (1)
|
Number |
Date |
Country |
Parent |
09450520 |
Nov 1999 |
US |
Child |
09992524 |
Nov 2001 |
US |